Abstract
Transforming growth factor-beta (TGF-β) is a multifunctional growth factor with a wide range of potential effects on growth, differentiation, extracellular matrix accumulation and the immune system. It has been implicated in many cardiovascular disorders. TGF-β actions are mediated via a complex between its type I and type II receptors resulting in the phosphorylation of receptor-specific Smads followed by their passage to the nucleus where they influence many transcriptional responses. TGF-β has important roles in the development of the neointima and constrictive remodeling associated with angioplasty. In atherosclerosis its actions are yet to be fully elucidated but its ability to control the immune system has profound effects on lesion development, particularly by influencing the types of lesions that develop. TGF-β can also induce arteriogenesis and markedly influences angiogenic processes, possessing both pro- and anti-angiogenic effects. It is also a major contributor to the development of various cardiovascular fibrotic disorders including those in the vasculature, heart and kidney. Targeting TGF-β prevents neointima formation and the constrictive remodeling associated with angioplasty and also prevents the development of many fibrotic disorders. This review summarizes TGF-β signaling pathways, the mechanisms by which TGF-β contributes to many of these cardiovascular diseases and examines the therapeutic potential of targeting TGF-β actions in preventing these disorders.
Keywords: transcription, dna binding proteins, transforming growth factor, antifibrotic effects
Current Vascular Pharmacology
Title: Transforming Growth Factor-β, Cell Signaling and Cardiovascular Disorders
Volume: 3 Issue: 1
Author(s): Alex Agrotis, Natalia Kalinina and Alex Bobik
Affiliation:
Keywords: transcription, dna binding proteins, transforming growth factor, antifibrotic effects
Abstract: Transforming growth factor-beta (TGF-β) is a multifunctional growth factor with a wide range of potential effects on growth, differentiation, extracellular matrix accumulation and the immune system. It has been implicated in many cardiovascular disorders. TGF-β actions are mediated via a complex between its type I and type II receptors resulting in the phosphorylation of receptor-specific Smads followed by their passage to the nucleus where they influence many transcriptional responses. TGF-β has important roles in the development of the neointima and constrictive remodeling associated with angioplasty. In atherosclerosis its actions are yet to be fully elucidated but its ability to control the immune system has profound effects on lesion development, particularly by influencing the types of lesions that develop. TGF-β can also induce arteriogenesis and markedly influences angiogenic processes, possessing both pro- and anti-angiogenic effects. It is also a major contributor to the development of various cardiovascular fibrotic disorders including those in the vasculature, heart and kidney. Targeting TGF-β prevents neointima formation and the constrictive remodeling associated with angioplasty and also prevents the development of many fibrotic disorders. This review summarizes TGF-β signaling pathways, the mechanisms by which TGF-β contributes to many of these cardiovascular diseases and examines the therapeutic potential of targeting TGF-β actions in preventing these disorders.
Export Options
About this article
Cite this article as:
Agrotis Alex, Kalinina Natalia and Bobik Alex, Transforming Growth Factor-β, Cell Signaling and Cardiovascular Disorders, Current Vascular Pharmacology 2005; 3 (1) . https://dx.doi.org/10.2174/1570161052773951
DOI https://dx.doi.org/10.2174/1570161052773951 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Systematic Review of Overweight, Obesity, and Type 2 Diabetes Among Asian American Subgroups
Current Diabetes Reviews Progress in the Rational Design for Polypharmacology Drug
Current Pharmaceutical Design Editorial (Thematic Issue: Therapies Targeting Oxidative Stress for Human Diseases: Where Are We Now?)
Current Pharmaceutical Biotechnology The Molecular Concept of Atheromatous Plaques
Current Drug Targets Contextualizing Genetics for Regional Heart Failure Care
Current Cardiology Reviews Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research Retinoid-Induced Limb Malformations
Current Pharmaceutical Design Pharmacogenomics of Cardiovascular Complications in Diabetes and Obesity
Recent Patents on Biotechnology Ezetimibe and Vascular Endothelial Function
Current Vascular Pharmacology Resisting the Sun with Vitamin D
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Inflammation Markers in Essential Hypertension
Medicinal Chemistry MicroRNAs in Arterial Hypertension
Current Topics in Medicinal Chemistry Recent Progress in the Development of Natural ent-Kaurane Diterpenoids with Anti-tumor Activity
Mini-Reviews in Medicinal Chemistry The Complex Biology of FOXO
Current Drug Targets Doppler Haemodynamics of Cerebral Venous Return
Current Neurovascular Research Exploitation of Some Natural Products for the Prevention and/or Nutritional Treatment of SARS-CoV2 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Benzothiazole Derivatives: Novel Inhibitors of Methylglyoxal Mediated Glycation of Proteins In Vitro
Medicinal Chemistry An Update on Developments in Female Hormonal Contraception
Current Women`s Health Reviews Emerging Pharmacological Treatments to Prevent Abdominal Aortic Aneurysm Growth and Rupture
Current Pharmaceutical Design Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme
Current Clinical Pharmacology